Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Meta-Analysis
19 March 2026

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment

Authors: Austin Kulasekararaj https://orcid.org/0000-0003-3180-3570 [email protected], Phillip Scheinberg https://orcid.org/0000-0002-9047-4538, Maria-Magdalena Balp https://orcid.org/0000-0002-8612-7680, Olivier Somenzi https://orcid.org/0009-0007-4087-8802, Anggie Wiyani https://orcid.org/0000-0002-5203-9797, Josefin Snellman https://orcid.org/0009-0003-6634-3823, Sarah Walsh https://orcid.org/0000-0003-2988-6506, Katharina Pannagl https://orcid.org/0009-0002-2505-1405, Jason Steenkamp https://orcid.org/0009-0006-0685-069X, and Régis Peffault de Latour https://orcid.org/0000-0001-6222-4753Author Info & Affiliations
Volume 15, Number 4
https://doi.org/10.57264/cer-2025-0167
PDFFormats

Abstract

This study conducted an indirect treatment comparison (ITC) of iptacopan, the first oral monotherapy targeting factor B, versus pegcetacoplan, a subcutaneous infusion targeting complement component 3, in patients with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia despite complement component 5 inhibitors (C5i). An unanchored matching adjusted ITC was performed, using phase III APPLY-PNH and PEGASUS studies, identified by a systematic literature review. The outcomes were: change from baseline (CfB) in hemoglobin (Hb), with and without post-transfusion data, CfB in lactate dehydrogenase (LDH), CfB in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, transfusion avoidance, and serious adverse events. Two adjustment scenarios were analyzed: (A) baseline Hb, sex, transfusion history ≤12 months, and (B) scenario A plus reticulocyte count, baseline LDH and age. After matching and adjusting, baseline characteristics were similar across trials. Iptacopan showed greater Hb improvements than pegcetacoplan with post-transfusion data (mean difference – scenario A: 1.05 g/dl; p < 0.001, scenario B: 0.76 g/dl; p = 0.018) and without (A: 1.31 g/dl; p < 0.001, B: 1.01 g/dl; p = 0.014). Odds of transfusion avoidance were higher with iptacopan (A: odds ratio [OR] = 9.17, p = 0.013; B: OR = 12.71, p = 0.009). No significant difference was noted in CfB in LDH and FACIT-Fatigue score. These findings suggest that iptacopan may improve Hb levels and reduce transfusion dependency compared with pegcetacoplan in PNH patients with residual anemia despite C5i and must be interpreted in the context of ITCs.

Plain language summary

What is this article about?

This study compared two newer medications for paroxysmal nocturnal hemoglobinuria (PNH), iptacopan and pegcetacoplan, to see which works better for patients who are still experiencing anemia despite standard treatment. Because no clinical trial has compared these drugs directly, a statistical method was used to match patient data from two separate studies, ensuring the groups were as similar as possible in areas like starting hemoglobin levels and previous transfusion history.

What were the results?

The results showed that patients taking iptacopan had significantly greater improvements in their hemoglobin levels and were much more likely to avoid the need for blood transfusions compared with those on pegcetacoplan. However, there were no significant differences between the two drugs in reducing fatigue or hemolysis.

What do the results mean?

While these findings suggest iptacopan may be more effective at raising hemoglobin levels and reducing transfusion dependency, they are associated with limitations because they are based on a small number of patients and should be confirmed with future direct comparisons.

Supplementary Material

File (supplementary materials.docx)
Download, DOCX (211.35 KB)

References

Papers of special note have been highlighted as: • of interest
1.
Brodsky R. Paroxysmal nocturnal hemoglobinuria. Blood 124(18), 2804–2811 (2014).
PubMed
Google Scholar
2.
Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat. Rev. Dis. Primers 3(1), 1–14 (2017).
Google Scholar
3.
Hillmen P, Lewis S, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333(19), 1253–1258 (1995).
PubMed
Google Scholar
4.
Food and Drug Administration. Soliris. (2019).
Google Scholar
5.
Kelly R, Hill A, Arnold L et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117(25), 6786–6792 (2011).
PubMed
Google Scholar
6.
Lee J-W, Bachman ES, Aguzzi R et al. Immediate, complete, and sustained inhibition of C5 with ALXN1210 reduces complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH): interim analysis of a dose-escalation study. Blood 128(22), 2428 (2016).
Google Scholar
7.
Lee J, Sicre de Fontbrune F, Wong Lee Lee L et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133(6), 530–539 (2019).
PubMed
Google Scholar
8.
Kulasekararaj AG, Hill A, Rottinghaus ST et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study. Blood 133(6), 540–549 (2019).
PubMed
Google Scholar
9.
Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350(6), 552–559 (2004).
PubMed
Google Scholar
10.
Risitano AM, Marotta S, Ricci P et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front. Immunol. 10, 1157 (2019).
PubMed
Google Scholar
11.
Dingli D, Matos JE, Lehrhaupt K et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann. Hematol. 101(2), 251–263 (2022).
PubMed
Google Scholar
12.
Panse J, Sicre de Fontbrune F, Burmester P et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: patient-reported insights on symptoms and quality of life. Eur. J. Haematol. 109(4), 351–363 (2022).
PubMed
Google Scholar
13.
Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355(12), 1233–1243 (2006).
PubMed
Google Scholar
14.
Debureaux P-E, Kulasekararaj AG, Cacace F et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant. 56(10), 2600–2602 (2021).
PubMed
Google Scholar
15.
Sicre de Fontbrune F, Burmester P, Piggin M et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective. Hematology 27(1), 1140–1151 (2022).
PubMed
Google Scholar
16.
Food and Drug Administration. Empaveli highlights of prescribing information. (2023). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215014s002lbl.pdf
Google Scholar
17.
European Medicines Agency. Aspaveli (pegcetacoplan) summary of product characteristics (SMPC). (2022). Last updated: 14 June 2022. Available from: Https://www.Ema.Europa.Eu/en/documents/product-information/aspaveli-epar-product-information_en.Pdf
Google Scholar
18.
Hillmen P, Szer J, Weitz I et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 384(11), 1028–1037 (2021).
PubMed
Google Scholar
• Primary publication of one of the clinical trials that informed this indirect treatment comparison (ITC).
19.
Schubart A, Anderson K, Mainolfi N et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc. Natl Acad. Sci. USA 116(16), 7926–7931 (2019).
PubMed
Google Scholar
20.
Risitano AM, Röth A, Soret J et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, Phase II, proof-of-concept trial. Lancet Haematol. 8(5), e344–e354 (2021).
PubMed
Google Scholar
21.
Food and Drug Administration. Fabhalta highlights of prescribing information. (2023). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218276s001lbl.pdf
Google Scholar
22.
European Medicines Agency. Fabhalta summary of product characteristics. (2023). Available from: https://www.ema.europa.eu/en/documents/product-information/fabhalta-epar-product-information_en.pdf
Google Scholar
23.
Peffault de Latour R, Roth A, Kulasekararaj A et al. Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 390(11), 994–1008 (2024).
PubMed
Google Scholar
• Primary publication of one of the clinical trials that informed this ITC.
24.
Phillippo D, Ades T, Dias S et al. NICE DSU TSD 18: Methods for population-adjusted indirect comparisons in submissions to NICE. NICE Decision Support Unit, UK (2016).
Google Scholar
• The primary methodological approach used in this ITC.
25.
NICE. NICE Health Technology Evaluations: The Manual [PMG36]. 31 January 2023. Available from: https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation
Google Scholar
26.
Phillippo DM, Dias S, Elsada A, Ades A, Welton NJ. Population adjustment methods for indirect comparisons: a review of national institute for health and care excellence technology appraisals. Int. J. Technol. Assess. Health Care 35(3), 221–228 (2019).
PubMed
Google Scholar
27.
Higgins J, Thomas J, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions, Version 6.3. (2022). Available from: http://www.training.cochrane.org/handbook
Google Scholar
28.
Munro I, Shodimu V, Webb N et al. SA52 efficacy of clinical interventions in paroxysmal nocturnal hemoglobinuria patients previously treated with C5 inhibitors: a systematic literature review. Value Health 27(12), S624 (2024).
Google Scholar
29.
Novartis Pharmaceuticals. Study of efficacy and safety of twice daily oral LNP023 in adult PNH patients with residual anemia despite anti-C5 antibody treatment (APPLY-PNH). (2020). Available from: https://clinicaltrials.gov/study/NCT04558918?a=7
Google Scholar
30.
Apellis Pharmaceuticals Inc. Study to evaluate the efficacy and safety of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH). (2018). Available from: https://clinicaltrials.gov/study/NCT03500549
Google Scholar
31.
Remiro-Azocar A, Heath A, Baio G. Methods for population adjustment with limited access to individual patient data: a review and simulation study. Res. Synth. Methods 12(6), 750–775 (2021).
PubMed
Google Scholar
32.
Signorovitch J, Sikirica V, Erder M et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940–947 (2012).
PubMed
Google Scholar
33.
R Core Team. R: a language and environment for statistical computing. (2021). Available from: https://www.R-project.org/
Google Scholar
34.
Hainmueller J. Ebal: entropy reweighting to create balanced samples. (2022). Available from: https://CRAN.R-project.org/package=ebal
Google Scholar
35.
de Latour RP, Kulasekararaj A, Dingli D et al. Anchored indirect treatment comparison finds comparable effects of pegcetacoplan and iptacopan in paroxysmal nocturnal haemoglobinuria. Eur. J. Haematol. 115(2), 125–133 (2025).
PubMed
Google Scholar